Antiemetic Guideline Adherence: Challenges and Opportunities for Oncology Nurses With Rebecca Clark-Snow, RN, BSN, OCN

The introduction of effective antiemetic regimens in recent years has led many clinicians to assume that CINV is no longer a major problem. However, nausea and vomiting are frequent complications of cancer treatment, occurring in up to 80% of patients receiving chemotherapy. Although CINV can be prevented in most patients with the use of guideline-recommended antiemetic regimens, Rebecca Clark-Snow, RN, BSN, OCN and colleagues (2018) recently revealed low adherence to antiemetic guidelines among...
Continue reading

Hepatocellular Carcinoma: Current Challenges and Future Directions With Thomas A. Abrams, MD

Hepatocellular carcinoma (HCC) is the sixth most common tumor globally. Patients with HCC have a dismal prognosis, with a 5-year survival rate of 18%. Thomas A. Abrams, MD, assistant professor of medicine at Harvard Medical School, spoke with i3 Health about how strong physician-patient relationships and a multidisciplinary approach can facilitate the management of HCC and improve outcomes.  

Continue reading

Best Practices in Thyroid Cancer Management With Jochen H. Lorch, MD, MS

Thyroid cancer is one of the most prevalent cancers in the United States. An estimated 56,870 new cases are diagnosed annually, and 2,010 people die of the disease. Thyroid cancer is typically more aggressive in men than women and becomes increasingly lethal in those older than age 40. The dearth of data from well-designed trials has led to confusion over the optimal management strategies for individual patients. In this interview, Jochen Lorch, MD, MS, Assistant Professor of Medicine at Harvard...
Continue reading

Metastatic Castration-Resistant Prostate Cancer: Treatment Selection and Sequencing With Tanya Dorff, MD

Prostate cancer is the most common tumor type among men in the United States. Typically, androgen deprivation therapy is administered for progressive disease. However, castration resistance or unresponsiveness to androgen deprivation therapy or to antiandrogens frequently develops over time. The transition from castration-sensitive to castration-resistant disease has yet to be understood and represents a significant unmet need. Metastatic castration-resistant prostate cancer (CRPC) is the primar...
Continue reading

Veno-Occlusive Disease: An Interview with Phyllis McKiernan, APN, MSN, OCN® and Michelle N. Rickard, DNP, CPNP-AC, CHPPN, BMTCN, CPON

Veno-occlusive disease (VOD) is a potentially life-threatening complication of hematopoietic stem cell transplant. In patients with severe cases, the mortality rate has been estimated to be greater than 80%. In this exclusive interview, Phyllis McKiernan, APN, MSN, OCN and Michelle Rickard, DNP, CPNP-AC, CHPPN, BMTCN, CPON spoke with i3 Health about challenges, patient education strategies, and best practices in nursing management of adult and pediatric patients with VOD.​

Continue reading

Copyright © 2020 i3 Health. All rights reserved.